Summit Therapeutics PLC

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver-, and society-friendly therapies. Its lead candidate is ivonescimab, a bispecific antibody that combines PD-1 blockade with anti-angiogenesis for immunotherapy in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Ivonescimab is also being studied in combination with chemotherapy in Phase III trials for EGFR-mutated locally advanced or metastatic non-squamous NSCLC, first-line metastatic NSCLC, and first-line unresectable metastatic CRC. The company markets its products in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, and was founded in 2003 with headquarters in Miami, Florida.